Chinese officials rolled out a plan to improve drug standards and monitoring over the next 5 years, saying "[m]edicinal safety is in a high-risk stage." Among the goals are stepped-up monitoring of adverse events, a credit-rating system, post-marketing surveillance and severe punishments for counterfeiters and misbehaving drug executives. Report